Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.53 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743042 | 1.00 | DPP4 (0.53) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL29619671 | 1.00 | DPP4 (0.53) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL743991 | 1.00 | DPP4 (0.53) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL25663563 | 1.00 | DPP4 (0.53) | DPP4DPP7CYP3A4DPP8 | |
| Hydrochloric Acid SCHEMBL3702345 | 0.98 | DPP4 (0.53) | DPP4DPP7DPP8 | |
| SCHEMBL28687928 | 0.86 | DPP4 (0.51) | DPP4DPP7CYP3A4DPP8 | |
| Mandelic Acid SCHEMBL30307007 | 0.85 | DPP4 (0.48) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL1644943 | 0.85 | DPP4 (0.51) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL22950634 | 0.85 | DPP4 (0.49) | DPP4DPP7CYP3A4DPP8 | |
| SCHEMBL22950624 | 0.85 | DPP4 (0.49) | DPP4DPP7CYP3A4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023012819-A1 | RECOMBINANT TRANSAMINASE POLYPEPTIDES | QUANTUMZYME LLP (IN) | 2023-02-09 | — | — | WO | claimed |
| US-8846916-B2 | Sitagliptin synthesis | GENERICS [UK] LIMITED (GB) | 2014-09-30 | — | — | US | claimed |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | claimed |
| EP-2430025-A1 | SITAGLIPTIN SYNTHESIS | Generics [UK] Limited (GB) | 2012-03-21 | — | — | EP | claimed |
| WO-2010131025-A1 | SITAGLIPTIN SYNTHESIS | GENERICS [UK] LIMITED (GB) | 2010-11-18 | — | — | WO | claimed |
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | claimed |
| US-11932886-B2 | Engineered transaminase polypeptides and uses thereof | ENZYMASTER (NINGBO) BIO-ENGINEERING CO., LTD. (CN) | 2024-03-19 | — | — | US | disclosed |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2023021529-A1 | IMPROVED ENZYMATIC SYNTHESIS OF SITAGLIPTIN OR ITS SALTS THEREOF | FERMENTA BIOTECH LIMITED (IN) | 2023-02-23 | — | — | WO | disclosed |
| WO-2021017645-A1 | RACEMIC PREPARATION METHOD FOR CHIRAL β-AMINO ACID AND DERIVATIVE THEREOF | 浙江九洲药业股份有限公司 | 2021-02-04 | — | — | WO | disclosed |
| US-20200332321-A1 | ENGINEERED TRANSAMINASE POLYPEPTIDES AND USES THEREOF | Enzymaster (Ningbo) Bio-Engineering Co., Ltd (CN) | 2020-10-22 | — | — | US | disclosed |
| EP-2694466-B1 | PREPARATION OF SITAGLIPTIN INTERMEDIATES | LEK PHARMACEUTICALS (SI) | 2018-10-24 | — | — | EP | disclosed |
| EP-2861598-B1 | NEW SYNTHETIC ROUTE FOR THE PREPARATION OF ß-AMINOBUTYRYL SUBSTITUTED 5,6,7,8-TETRAHYDRO[1,4]DIAZOLO[4,3-a]PYRAZIN-7-YL COMPOUNDS | LEK PHARMACEUTICALS (SI) | 2017-10-25 | — | — | EP | disclosed |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | MYLAN INDIA PRIVATE LIMITED (IN) | 2012-05-03 | — | — | US | disclosed |
| EP-2430025-A1 | SITAGLIPTIN SYNTHESIS | Generics [UK] Limited (GB) | 2012-03-21 | — | — | EP | disclosed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | disclosed |
| WO-2010131025-A1 | SITAGLIPTIN SYNTHESIS | GENERICS [UK] LIMITED (GB) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010122578-A2 | PROCESS FOR THE PREPARATION OF SITAGLIPTIN AND ITS INTERMEDIATES | MSN LABORATORIES LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108598-A1 | SITAGLIPTIN SYNTHESIS | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885CYP3A4 53/4885 |
| US-20230142248-A1 | METHOD FOR RACEMIC PREPARATION OF CHIRAL B-AMINO ACIDS AND DERIVATIVES THEREOF | GLP1R, SRR, GIPR | DPP4 7/4885DPP7 12/4885CYP3A4 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.